TOTUM-854 – Arterial hypertension

Arterial hypertension, the first cardiovascular risk factor

Arterial hypertension (AHT) is the world’s most prevalent chronic disease and the leading cause of premature death. It affects all countries, regardless of their level of development.

In the long term, AHT weakens the arteries and promotes the onset of serious diseases, predominantly heart attacks, strokes, peripheral arterial diseases and kidney failure. It is the primary cardiovascular risk factor in the world.

 

Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; Prise en charge de l’hypertension artérielle de l’adulte, Recommandation de bonne pratique, HAS, 2016 www.has-sante.fr/jcms/c_2059286/fr/prise-en-charge-de-l-hypertension-arterielle-de-l-adulte

Key Figures

First chronic disease in the world

1.13

billion people worldwide with arterial hypertension in 2015. 30 to 45% of adults are hypertensive.

Source: 2018 ESC/ESH Guidelines for the management of arterial hypertension.

Hypertension thresholds

140

/90 mmHG, is the defined threshold for arterial hypertension in Europe. In the United States, the threshold value starts at 130/80 mmHg.

Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

TOTUM-854: a promising candidate in the fight against arterial hypertension, to prevent the risk of cardiovascular diseases

TOTUM-854 is a unique and patented combination of plant extracts, designed to reduce arterial blood pressure, in people with a moderate elevation in blood pressure.

It is a new opportunity in a  1-billion people market worldwide. Currently no non-drug product with solid clinical evidence nor health claims for blood pressure reduction is available.

Clinical Phase II developpment pending

The TOTUM-854 program is ready to enter clinical Phase II, to obtain a health claim related to blood pressure reduction, in Europe and North America.

With blood pressure reduction as primary objective, this Phase II study will have to show the active substance’s efficacy in a population with arterial hypertension, at risk of cardiovascular diseases.

Intellectual property

Patent applications have been filed for TOTUM-854 in more than 60 countries, including key territories: Europe, USA, Canada, China, Russia, Japan, Brazil, Australia.

The patent was granted in France in 2014, in the United States in 2018, in Europe in 2019 (39 countries), in Russia in 2020 with a high level of protection.

-